Drug Profile
856464
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Feb 2007 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
- 22 Apr 2005 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)